Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* ECOG Status: PS 0-1 \& PS 2~* Subjects with histologically or cytologically-documented SqNSCLC~* Subjects must have experienced disease progression or recurrence during or after one prior platinum doublet-based chemotherapy regimen~* Subjects must have evaluable disease by CT or MRI per RECIST 1.1 criteria~* Subjects with treated or asymptomatic CNS metastases~* Prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration~* Prior lines of antineoplastic therapy, including hemotherapy, hormonal therapy, immunotherapy, surgical resection of lesions, non-palliative radiation therapy, or standard or investigational agents for treatment of NSCLC, must be completed 28 days prior to the first dose of nivolumab~* Males and Females, ages 18 or older~Exclusion Criteria:~* Subjects with untreated, symptomatic CNS metastases~* Subjects with carcinomatous meningitis~* Subjects with active, known or suspected autoimmune disease.~* Subjects who received prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways) or who have previously taken part in a randomized BMS clinical trial for nivolumab or ipilimumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A: Treatment - Nivolumab (Type: EXPERIMENTAL): Nivolumab IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).